Merck boosts its full-year outlook as third-quarter earnings top estimates following strong demand for its blockbuster cancer ...

Wall Street rallied higher as investors digested upbeat earnings from big tech companies during the week. The Nasdaq gained 2 ...

With vaccine sales on the decline, these are tough times for Merck to launch its new pneumococcal shot Capvaxive. | With ...

The combination of Merck's Welireg and Eisai's Lenvima has not yet shown statistical significance in extending overall ...

Q3 earnings beat estimates, but shares dip as 2025 sales outlook narrows. Get key highlights and pharma market insights.

Merck & Co beat third-quarter (3Q) sales expectations on strong results from its pneumonia vaccine as the company works to ...

Merck is breaking ground on a new 400,000-square-foot manufacturing facility in Elkton, Virginia, as part of its $70 billion ...

Merck and Japan's Eisai said on Wednesday they will shut down a late-stage study testing an experimental combination therapy ...

Merck's Q3 2025 results saw huge growth in Winrevair and Capvaxive sales. Check out why I maintain my Strong Buy rating on ...

The company will begin its domestic investment by starting construction on a $3 billion pharmaceutical manufacturing site in ...

Merck's KEYNOTE-B96 trial shows Keytruda with chemotherapy improves survival in platinum-resistant recurrent ovarian cancer with a consistent safety profile.

Virginia will be home to a workforce training center preparing thousands of people each year for a career in the pharmaceutical industry.